INLURIYO

NDA 218881 · New Drug Application (NDA) Prescription

IMLUNESTRANT TOSYLATE

Sponsor (Drugs@FDA)
ELI LILLY AND CO Company: ELI LILLY & Co (LLY)
First approved
Latest action

Drugs on HealthTrade

Drugs whose FDA actions or confirmed applications cite this number. A drug listed from this record shows “Not yet reviewed” on its page until an editor checks it.

Products

Drugs@FDA products under NDA 218881, with Orange Book listing details
ProductName and ingredientForm and strengthMarketing statusTE codeReferenceOrange Book
001 INLURIYO IMLUNESTRANT TOSYLATE TABLET;ORAL EQ 200MG BASEPrescription– Reference listed drug, Reference standard RXApproved

Submissions

FDA submissions for NDA 218881, newest first
SubmissionStatusStatus dateReviewClassDocuments
Supplement 1ApprovedstandardEfficacyLetter for Supplement 1 (opens in a new tab)Label for Supplement 1 (opens in a new tab)
Original 1ApprovedstandardType 1 - New Molecular EntityLetter for Original 1 (opens in a new tab)Label for Original 1 (opens in a new tab)

Orange Book patents

2 patents listed, as the Orange Book prints them.

Orange Book patents for NDA 218881
PatentExpiresClaimsUse codeSubmitted
10654866Product 001 Drug substance, Drug product U-4278
11117902Product 001 Drug substance, Drug product U-4278

Orange Book exclusivities

Orange Book exclusivities for NDA 218881
CodeProductExpires
NCE001

Codes as the Orange Book prints them; its preface explains each code.

Prescription labels

No human prescription label in openFDA cites this application.

NDC products

1 product in the NDC directory with this application number.

NDC directory products for NDA 218881
Product NDCNameLabelerForm and routeCategoryMarketing dates
0002-1717 in openFDA (opens in a new tab) Inluriyo imlunestrantEli Lilly and Company TABLET, FILM COATED ORALNDA From

FDA recalls load here.

FDA drug shortages load here.

Sources

Data provided by the U.S. Food and Drug Administration. Showing it here is not an FDA endorsement. openFDA asks: “Do not rely on openFDA to make decisions regarding medical care.”

Patent and exclusivity dates are as FDA lists them and can change. Nothing on this page is medical or investment advice.